Casey Claypool, OD
Optometrist · Spokane Valley, WANPI 1447480579
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $197,822 of the $323,442 with a category attached, or 61.2%. 32 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 27.1% of the total. 2025 is the largest year on record at $86,618, 3.9 times the $22,241 reported in 2019. Among optometrist clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 684 payments — averaging $472.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$88K
- Bausch & Lomb Americas Inc.$76K
- Sun Pharmaceutical Industries Inc.$58K
- Tarsus Pharmaceuticals, Inc.$50K
- AbbVie$27K
- Biotissue Holdings Inc.$17K
- plus $7K from 26 others
Across 2 payments — averaging $7000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Surgical Vision, Inc.$14K
What the payments were for
- Consulting fees$77,49624%
- Speaking & faculty fees$197,82261%
- Travel & lodging$32,31110%
- Food & beverage$15,7995%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 67 | $87,814 |
| Bausch & Lomb Americas Inc. | 130 | $76,493 |
| Sun Pharmaceutical Industries Inc. | 143 | $57,667 |
| Tarsus Pharmaceuticals, Inc. | 78 | $50,479 |
| AbbVie(2 entities) | 85 | $27,109 |
| Biotissue Holdings Inc. | 37 | $17,208 |
| Lumenis, Inc | 1 | $2,000 |
| Mallinckrodt Hospital Products Inc. | 30 | $814 |
| Glaukos Corporation | 4 | $634 |
| Novartis | 14 | $424 |
| Dompe US, Inc. | 16 | $417 |
| Alcon | 9 | $380 |
| Mallinckrodt Enterprises LLC | 10 | $350 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 18 | $345 |
| Oyster Point Pharma, Inc. | 9 | $325 |
| Shire North American Group Inc | 6 | $184 |
| Aerie Pharmaceuticals, Inc. | 7 | $173 |
| Rxsight Inc | 1 | $125 |
| Merz Pharmaceuticals, LLC | 4 | $97 |
| Carl Zeiss Meditec, Inc. | 1 | $60 |
| Thea Pharma Inc. | 2 | $48 |
| Johnson & Johnson Vision Care, Inc. | 2 | $44 |
| Lumibird Medical Inc. | 1 | $40 |
| Astellas Pharma US Inc | 1 | $34 |
| Harrow Eye, LLC | 1 | $32 |
| Genentech USA, Inc. | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Carl Zeiss Meditec USA, Inc. | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Amgen | 1 | $16 |
| Ivantis, Inc | 1 | $15 |
| Sight Sciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$73,756
- XIIDRA$60,225
- CEQUA$55,096
- XDEMVY$43,370
- MEIBOMIAN GLAND EVALUATOR$27,003
- VUITY$25,742
- Prokera$11,509
- LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE)$9,648
- Tecnis IOL$9,000
- One Series Ultra IOL Delivery System$8,455
- TearScience Lipiflow System$6,151
- TearScience Lipiscan System$6,151
- TearScience Lipiview System$6,151
- One Series Ultra$4,500
- LIPIVIEW OCULAR SURFACE INTERFEROMETER$3,008
- TearScience Activators$2,211
- Tecnis Symfony IOL$1,115
- Tecnis Multifocal Family of 1-piece IOLS$839
- BLINK NUTRITEARS$500
- BROMSITE$205
How this compares
$323,442 in reported general payments places this provider in the 95th percentile of 1,267 optometrist providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 30 | $1,237,904 |
| ActharCorticotropin | 15 | $1,023,845 |
| RestasisCyclosporine | 353 | $349,702 |
| XdemvyLotilaner | 82 | $153,852 |
| CequaCyclosporine | 119 | $143,214 |
| XiidraLifitegrast | 111 | $134,357 |
| MieboPerfluorohexyloctane/Pf | 105 | $88,811 |
| TyrvayaVarenicline Tartrate | 87 | $77,427 |
| Cyclosporine | 146 | $66,444 |
| VevyeCyclosporine | 22 | $22,288 |
| Fluorometholone | 142 | $11,408 |
| LumiganBimatoprost | 18 | $8,546 |
| VyzultaLatanoprostene Bunod | 15 | $6,364 |
| Loteprednol Etabonate | 19 | $5,659 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $3,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $417 | $1,237,90430 claims |
| Mallinckrodt Hospital Products Inc.Acthar | $814 | $1,023,84515 claims |
| AbbVieRestasis, Lumigan | $27,109 | $358,248371 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $76,493 | $229,532231 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $50,479 | $153,85282 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $57,667 | $143,214119 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $325 | $77,42787 claims |
| Harrow Eye, LLCVevye | $32 | $22,28822 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $345 | $5,65919 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $173 | $3,99412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,267 optometrist providers in Washington.
Other optometrist in Spokane Valley
- David KadingKirkland$397K
- Peter BergenskeOtis Orchards$355K
- Charles ClaytonBellevue$195K
- Herminder BoparaiBellevue$131K
- Rajiv PatelVancouver$118K
- Alan ChousTacoma$115K
- Roya HabibiSeattle$109K
- Bryan HeitmeyerKent$67K
- Kevin OsborneMoses Lake$47K
- Jay HaynieTacoma$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.